Marksans Pharma Hits Historic Triple: Highest Revenue, EBITDA & PAT

Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) reported the financial results today for the quarter and full-year ended on March 31, 2026.

Mark Saldanha, Managing Director of the Company, said, "FY26 has been a milestone year for Marksans Pharma, we successfully delivered on our guidance with highest-ever total income at ~₹3,033 crore, EBITDA at ₹601 crore (margin 20.4%) and an all-time high PAT of ₹420 crore.

Growth was led by a series of new launches across markets through the year, including our Rx branded portfolio in Australia. UK delivered a very strong recovery in Q4 achieving its highest-ever quarterly revenue. Growth was also aided by 112 new SKUs launched in the US market. We also strengthened our global footprint by entering new markets including Germany, Canada, and Ireland.

We closed the year with a cash balance of ~₹990 crore, extending our multi-year track record of net cash positive, with the major capex cycle now nearly complete.

While we are monitoring emerging input cost pressures closely, our underlying momentum, balance sheet strength, and disciplined execution position us well to continue delivering sustainable growth and long-term shareholder value."

FY26 Financial Highlights

- Total Income stood at Rs. 3,033 cr., up by 12.8% YoY
- Gross profit came in at Rs. 1,674 cr., up by 13.2% YoY, with a gross margin of 56.7%
- EBITDA stood at Rs. 601 cr. with an EBITDA margin of 20.4%
- EPS was at Rs. 9.2

Q4FY26 Financial Highlights

- Total Income stood at Rs. 891 cr., up by 23.1% YoY
- Gross profit stood at Rs. 466 cr., up by 21.5% YoY, with gross margin of 54.4%
- EBITDA stood at Rs. 195 cr., with a margin of 22.8%
- EPS was at Rs. 3.3

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 220.25 as compared to the previous close of Rs. 211.65. The total number of shares traded during the day was 92700 in over 1590 trades.

The stock hit an intraday high of Rs. 221.50 and intraday low of 214.00. The net turnover during the day was Rs. 20217893.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Pharmaceuticals Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate